Article
Given the advancement in both pathophysiology and precision-guided approaches for prostate cancer, we assembled a panel of expert urologists to discuss clinically important aspects of ADT that will assist busy clinician decision makers in their optimization of outcomes for their advanced prostate cancer population.
Expert Panel Discussion
The indications and selection of patients for androgen deprivation therapy (ADT) for men with advanced prostate cancer are often topics of debate, specifically regarding initiation indications, selection of an ADT option (reflective of mechanism of action and mode of administration), and recognized safety and tolerability issues.
Given the advancement in both pathophysiology and precision-guided approaches for prostate cancer, we assembled a panel of expert urologists to discuss clinically important aspects of ADT that will assist busy clinician decision makers in their optimization of outcomes for their advanced prostate cancer population.